A study evaluating of PEGPH20 for pancreatic cancer: Precision Promise pragramm

Trial Profile

A study evaluating of PEGPH20 for pancreatic cancer: Precision Promise pragramm

Planning
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Hyaluronidase (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2017 According to a Halozyme Therapeutics media release, this trial will be led by the Pancreatic Cancer Action Network.
    • 17 Oct 2016 New trial record
    • 04 Oct 2016 According to a Halozyme Therapeutics media release, Precision Promise plans to enroll patients at 12 initial consortium sites in Spring 2017. A companion diagnostic assay will be used for assessment of hyaluronan in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top